VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Earnings Estimates
Europe - Frankfurt Stock Exchange - FRA:VX1 - US92532F1003 - Common Stock
398 EUR
-0.95 (-0.24%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 8.931B 17.91% | 9.869B 10.51% | 11.02B 11.66% | 12.225B 10.93% | 13.257B 8.44% | 14.509B 9.44% | 16.003B 10.30% | 17.682B 10.49% | 19.191B 8.53% | 19.943B 3.92% | 21.412B 7.37% | 22.768B 6.33% | |
| EBITDA YoY % growth | 4.584B 57.66% | 4.54B -0.96% | 4.603B 1.37% | 5.49B 19.28% | 6.368B 15.99% | 7.164B 12.50% | 7.474B 4.33% | 8.591B 14.95% | 9.436B 9.84% | 10.293B 9.08% | 12.19B 18.43% | 12.636B 3.66% | |
| EBIT YoY % growth | 4.436B 59.44% | 4.359B -1.73% | 4.396B 0.84% | 5.338B 21.44% | 6.106B 14.39% | 6.884B 12.74% | 7.572B 9.99% | 8.651B 14.25% | 9.345B 8.02% | 10.143B 8.54% | 11.083B 9.27% | 11.674B 5.33% | |
| Operating Margin | 49.67% | 44.17% | 39.89% | 43.66% | 46.06% | 47.45% | 47.32% | 48.93% | 48.69% | 50.86% | 51.76% | 51.27% | |
| EPS YoY % growth | 14.89 14.36% | 15.22 2.22% | 0.29 -98.09% | 18.69 6,343.89% | 20.45 9.43% | 22.88 11.88% | 25.06 9.54% | 28.61 14.17% | 30.97 8.26% | 33.67 8.69% | 37.27 10.72% | 39.29 5.41% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | 5.19 30.39% | 4.93 21.35% | 5.05 11.83% | 5.16 7.57% | 5.24 0.92% |
| Revenue Q2Q % growth | 3.242B 11.33% | 3.188B 15.08% | 3.28B 10.64% | 3.335B 8.41% | 3.389B 4.53% |
| EBITDA Q2Q % growth | 1.477B 11.83% | 1.604B 48.89% | 1.547B 23.42% | 1.544B 10.70% | 1.491B 0.95% |
| EBIT Q2Q % growth | 1.46B 31.12% | 1.44B 39.96% | 1.449B 25.64% | 968.29M -21.96% | 1.473B 0.89% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2025 Q2Q % growth | 4.80 9.59% | 4.65 | 0.15 | 3.12% |
| Q2 2025 Q2Q % growth | 4.52 135.23% | 4.37 | 0.15 | 3.45% |
| Q1 2025 Q2Q % growth | 4.06 -14.71% | 4.37 | -0.31 | -7.20% |
| Q4 2024 Q2Q % growth | 3.98 -5.24% | 4.11 | -0.13 | -3.07% |
| Q3 2024 Q2Q % growth | 4.38 7.35% | 4.22 | 0.16 | 3.69% |
| Q2 2024 Q2Q % growth | -12.83 -429.82% | 3.00 | -15.83 | -527.57% |
| Q1 2024 Q2Q % growth | 4.76 56.07% | 4.14 | 0.62 | 14.85% |
| Q4 2023 Q2Q % growth | 4.20 11.70% | 4.18 | 0.02 | 0.36% |
| Q3 2023 Q2Q % growth | 4.08 1.75% | 4.05 | 0.03 | 0.66% |
| Q2 2023 Q2Q % growth | 3.89 8.06% | 3.96 | -0.07 | -1.75% |
| Q1 2023 Q2Q % growth | 3.05 -13.35% | 3.06 | -0.01 | -0.21% |
| Q4 2022 Q2Q % growth | 3.76 11.57% | 3.58 | 0.18 | 4.95% |
| Q3 2022 Q2Q % growth | 4.01 12.64% | 3.72 | 0.29 | 7.89% |
| Q2 2022 Q2Q % growth | 3.60 15.76% | 3.55 | 0.05 | 1.44% |
| Q1 2022 Q2Q % growth | 3.52 18.12% | 3.56 | -0.04 | -1.18% |
| Q4 2021 Q2Q % growth | 3.37 34.26% | 3.37 | 0.00 | 0.13% |
| Q3 2021 Q2Q % growth | 3.56 34.85% | 3.14 | 0.42 | 13.27% |
| Q2 2021 Q2Q % growth | 3.11 19.16% | 2.56 | 0.55 | 21.59% |
| Q1 2021 Q2Q % growth | 2.98 16.41% | 2.74 | 0.24 | 8.66% |
| Q4 2020 Q2Q % growth | 2.51 | 2.64 | -0.13 | -5.00% |
| Q3 2020 Q2Q % growth | 2.64 | 2.39 | 0.25 | 10.49% |
| Q2 2020 Q2Q % growth | 2.61 | 2.12 | 0.49 | 23.38% |
| Q1 2020 Q2Q % growth | 2.56 | 1.88 | 0.68 | 36.03% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2025 Q2Q % growth | 3.076B 10.99% | 3.114B | -37.6M | -1.21% |
| Q2 2025 Q2Q % growth | 2.965B 12.06% | 2.963B | 1.7M | 0.06% |
| Q1 2025 Q2Q % growth | 2.77B 2.96% | 2.91B | -139.8M | -4.80% |
| Q4 2024 Q2Q % growth | 2.912B 15.66% | 2.836B | 76M | 2.68% |
| Q3 2024 Q2Q % growth | 2.772B 11.61% | 2.778B | -6.1M | -0.22% |
| Q2 2024 Q2Q % growth | 2.646B 6.11% | 2.715B | -69.4M | -2.56% |
| Q1 2024 Q2Q % growth | 2.691B 13.30% | 2.63B | 60.6M | 2.30% |
| Q4 2023 Q2Q % growth | 2.518B 9.34% | 2.564B | -46.3M | -1.81% |
| Q3 2023 Q2Q % growth | 2.484B 6.39% | 2.55B | -66.5M | -2.61% |
| Q2 2023 Q2Q % growth | 2.493B 13.52% | 2.468B | 25.2M | 1.02% |
| Q1 2023 Q2Q % growth | 2.375B 13.22% | 2.384B | -9.2M | -0.39% |
| Q4 2022 Q2Q % growth | 2.303B 11.10% | 2.347B | -44.3M | -1.89% |
| Q3 2022 Q2Q % growth | 2.334B 17.65% | 2.271B | 63.3M | 2.79% |
| Q2 2022 Q2Q % growth | 2.196B 22.46% | 2.175B | 21.2M | 0.97% |
| Q1 2022 Q2Q % growth | 2.098B 21.64% | 2.118B | -20.5M | -0.97% |
| Q4 2021 Q2Q % growth | 2.073B 27.32% | 2.043B | 29.561M | 1.45% |
| Q3 2021 Q2Q % growth | 1.984B 28.99% | 1.893B | 91.164M | 4.82% |
| Q2 2021 Q2Q % growth | 1.793B 17.64% | 1.752B | 41.37M | 2.36% |
| Q1 2021 Q2Q % growth | 1.724B 13.81% | 1.69B | 34.305M | 2.03% |
| Q4 2020 Q2Q % growth | 1.628B | 1.616B | 11.82M | 0.73% |
| Q3 2020 Q2Q % growth | 1.538B | 1.515B | 23.271M | 1.54% |
| Q2 2020 Q2Q % growth | 1.524B | 1.413B | 111.485M | 7.89% |
| Q1 2020 Q2Q % growth | 1.515B | 1.313B | 202.107M | 15.39% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -0.35% | 3.71% | 0.02% | 1.53% |
| Revenue | -0.06% | -0.92% | -0.07% | 0.01% |